Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

This study has been completed.
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Christopher R. Flowers, Emory University Identifier:
First received: February 11, 2008
Last updated: February 17, 2016
Last verified: February 2016
Results First Received: February 17, 2016  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Lymphoma, B-Cell
Follicular Lymphoma
Interventions: Drug: Bortezomib
Biological: Rituximab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
All patients were recruited from Winship Cancer Institute of Emory University.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Treatment (VR-CHOP Regimen)

Phase I will identify the maximal tolerated doses of bortezomib and vincristine when used in a combination of bortezomib, rituximab and the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen.

In Phase II, the trial will evaluate the efficacy and safety of the MTD combination of VELCADE and rituximab-CHOP in additional subjects who have untreated follicular B-cell non-Hodgkin's lymphoma (B-NHL)(Grade 1, 2, 3a), small lymphocytic lymphoma, or marginal zone lymphoma.

Participant Flow for 2 periods

Period 1:   Phase I: Induction
    Treatment (VR-CHOP Regimen)  
STARTED     19  
COMPLETED     19  

Period 2:   Phase II: Maintenance
    Treatment (VR-CHOP Regimen)  
STARTED     30  
COMPLETED     29  
Diagnosis changed after re-review                 1  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Treatment (VR-CHOP Regimen)

INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.

MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity.

Baseline Measures
    Treatment (VR-CHOP Regimen)  
Number of Participants  
[units: participants]
[units: years]
Median (Full Range)
  (28 to 71)  
[units: participants]
Female     17  
Male     20  
Race (NIH/OMB)  
[units: participants]
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     11  
White     26  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
United States     37  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)   [ Time Frame: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks ]

2.  Secondary:   An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria   [ Time Frame: Following completion of therapy, up to 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Christopher R. Flowers, MD, MS
Organization: Emory University
phone: 404-778-3935

Publications of Results:

Responsible Party: Christopher R. Flowers, Emory University Identifier: NCT00634179     History of Changes
Other Study ID Numbers: IRB00002996
X05215 ( Other Identifier: Winship Cancer Institute )
Study First Received: February 11, 2008
Results First Received: February 17, 2016
Last Updated: February 17, 2016
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
United States: Data and Safety Monitoring Board